United States· US:61755-012_aa61176b-8199-47b9-ae53-66c4041f5ff5

Pasatru

A medicinal product containing garetosmab, registered in United States by Regeneron Pharmaceuticals, Inc..

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedPasatruATC—REGISTER NO.US:61755-012_aa61176b…PACKS LISTED1CHECKEDSeptember 27, 2026

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
GARETOSMAB
Manufacturer
Regeneron Pharmaceuticals, Inc.
Country
United States (US)
ATC code
—
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 1

  • ndc11
    61755-012-01

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/adeb3b2e-17fc-4515-a2e1-32786e57f4d9
GET /v1/drugs/adeb3b2e-17fc-4515-a2e1-32786e57f4d9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "INTRAVENOUS",
  "source": "ndc",
  "strength": "300",
  "substance": "GARETOSMAB",
  "productndc": "61755-012",
  "dosage_form": "INJECTION, SOLUTION, CONCENTRATE",
  "dea_schedule": null,
  "strength_unit": "mg/5mL",
  "application_number": "BLA761508",
  "marketing_category": "BLA"
}

See everything about garetosmab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.